Bank Of Montreal

Direxion Daily Small Cap Bull 3X ETF

SPDR S&P Retail ETF

ProShares UltraPro Dow30

ProShares UltraShort Bloomberg Natrl Gas

Guggenheim Solar ETF

Direxion Technology Bear 3X Shares

Materials Select Sector SPDR

ProShares Trust ProShares Short Bitcoin Strategy ETF

ProShares Bitcoin Strategy ETF

Direxion Daily Small Cap Bear 3X ETF

ProShares Ultra Bloomberg Natural Gas

Direxion Daily Technology Bull 3X ETF

ARK Innovation ETF

Direxion Dly S&P Oil&Gs Ex&Prd Br 3X ETF

Magal Security Systems Ltd.

Direxion Financial Bear 3X Shar

Direxion Daily Semicondct Bull 3X ETF

JELD-WEN Holding Inc. Common Stock

Las Vegas Sands Corp. Common Stock

Century Communities Inc. Common Stock

Kontoor Brands Inc. Common Stock

Bath & Body Works Inc.

RLJ Lodging Trust Common Shares of Beneficial Interest $0.01 par value

Leggett & Platt Incorporated Common Stock

Snap Inc. Class A Common Stock

Cleveland-Cliffs Inc. Common Stock

Civitas Resources Inc. Common Stock

Archer Aviation Inc. Class A Common Stock

AMC Entertainment Holdings Inc. Class A Common Stock

Oklo Inc.

QuantumScape Corporation Class A Common Stock

Sea Limited American Depositary Shares each representing one Class A Ordinary Share

Cameco Corporation Common Stock

Twilio Inc. Class A Common Stock

Spotify Technology S.A. Ordinary Shares

Cloudflare Inc. Class A Common Stock

Molina Healthcare Inc Common Stock

Click here to get full coverage on Theravance Biopharma Announces Approval of YUPELRI® (revefenacin) by China's NMPA - PR Newswire

Theravance Biopharma Announces Approval of YUPELRI® (revefenacin) by China's NMPA  PR Newswire

Theravance Biopharma Announces Approval of YUPELRI® (revefenacin) by China's NMPA - PR Newswire

Click here to get full coverage on TBPH-induced lung injury is induced by mitochondrial-derived ds-DNA-mediated inflammatory response - ScienceDirect.com

TBPH-induced lung injury is induced by mitochondrial-derived ds-DNA-mediated inflammatory response  ScienceDirect.com

TBPH-induced lung injury is induced by mitochondrial-derived ds-DNA-mediated inflammatory response - ScienceDirect.com

Click here to get full coverage on TBPH to Sell Remaining Trelegy Royalty Interest to GSK, Stock Rises - Yahoo Finance

TBPH to Sell Remaining Trelegy Royalty Interest to GSK, Stock Rises  Yahoo Finance

TBPH to Sell Remaining Trelegy Royalty Interest to GSK, Stock Rises - Yahoo Finance

Click here to get full coverage on Theravance Cashes Out Trelegy Royalties: $225M Deal Unlocks $1.5B Total Value from GSK - Stock Titan

Theravance Cashes Out Trelegy Royalties: $225M Deal Unlocks $1.5B Total Value from GSK  Stock Titan

Theravance Cashes Out Trelegy Royalties: $225M Deal Unlocks $1.5B Total Value from GSK - Stock Titan

Click here to get full coverage on TBPH to Sell Remaining Trelegy Royalty Interest to GSK, Stock Rises - Zacks Investment Research

TBPH to Sell Remaining Trelegy Royalty Interest to GSK, Stock Rises  Zacks Investment Research

TBPH to Sell Remaining Trelegy Royalty Interest to GSK, Stock Rises - Zacks Investment Research

Click here to get full coverage on Theravance Biopharma (NASDAQ:TBPH) shareholders are up 15% this past week, but still in the red over the last five years - simplywall.st

Theravance Biopharma (NASDAQ:TBPH) shareholders are up 15% this past week, but still in the red over the last five years  simplywall.st

Theravance Biopharma (NASDAQ:TBPH) shareholders are up 15% this past week, but still in the red over the last five years - simplywall.st

Click here to get full coverage on Why Is Theravance Bio (TBPH) Up 0.4% Since Last Earnings Report? - Nasdaq

Why Is Theravance Bio (TBPH) Up 0.4% Since Last Earnings Report?  Nasdaq

Why Is Theravance Bio (TBPH) Up 0.4% Since Last Earnings Report? - Nasdaq

Click here to get full coverage on TBPH Stock Price Target Increased Following Milestone Payment | TBPH Stock News - GuruFocus

TBPH Stock Price Target Increased Following Milestone Payment | TBPH Stock News  GuruFocus

TBPH Stock Price Target Increased Following Milestone Payment | TBPH Stock News - GuruFocus

Click here to get full coverage on Theravance stock rises as China OKs Yupelri (TBPH:NASDAQ) - Seeking Alpha

Theravance stock rises as China OKs Yupelri (TBPH:NASDAQ)  Seeking Alpha

Theravance stock rises as China OKs Yupelri (TBPH:NASDAQ) - Seeking Alpha

Click here to get full coverage on Theravance Biopharma, Inc.(NasdaqGM:TBPH) dropped from Russell 2000 Defensive Index - MarketScreener

Theravance Biopharma, Inc.(NasdaqGM:TBPH) dropped from Russell 2000 Defensive Index  MarketScreener

Theravance Biopharma, Inc.(NasdaqGM:TBPH) dropped from Russell 2000 Defensive Index - MarketScreener

Click here to get full coverage on Environmental Levels of Bis(2-ethylhexyl)-tetrabromophthalate (TBPH) Cause Thyroid Toxicity and Early Carcinogenic Signals in Juvenile Fish - ScienceDirect.com

Environmental Levels of Bis(2-ethylhexyl)-tetrabromophthalate (TBPH) Cause Thyroid Toxicity and Early Carcinogenic Signals in Juvenile Fish  ScienceDirect.com

Environmental Levels of Bis(2-ethylhexyl)-tetrabromophthalate (TBPH) Cause Thyroid Toxicity and Early Carcinogenic Signals in Juvenile Fish - ScienceDirect.com

Click here to get full coverage on Theravance Biopharma to Participate in an Upcoming Investor Conference - Stock Titan

Theravance Biopharma to Participate in an Upcoming Investor Conference  Stock Titan

Theravance Biopharma to Participate in an Upcoming Investor Conference - Stock Titan

Click here to get full coverage on Theravance Biopharma Inc (TBPH) Q3 2024 Earnings Call Highlights: Strong Sales Growth and ... - Yahoo Finance

Theravance Biopharma Inc (TBPH) Q3 2024 Earnings Call Highlights: Strong Sales Growth and ...  Yahoo Finance

Theravance Biopharma Inc (TBPH) Q3 2024 Earnings Call Highlights: Strong Sales Growth and ... - Yahoo Finance

Click here to get full coverage on Theravance Biopharma First Quarter 2025 Earnings: Misses Expectations - simplywall.st

Theravance Biopharma First Quarter 2025 Earnings: Misses Expectations  simplywall.st

Theravance Biopharma First Quarter 2025 Earnings: Misses Expectations - simplywall.st

Click here to get full coverage on Theravance Announces Publication of YUPELRI® (revefenacin) Area Under the Curve Spirometry Analysis in the International Journal of Chronic Obstructive Pulmonary Disease - PR Newswire

Theravance Announces Publication of YUPELRI® (revefenacin) Area Under the Curve Spirometry Analysis in the International Journal of Chronic Obstructive Pulmonary Disease  PR Newswire

Theravance Announces Publication of YUPELRI® (revefenacin) Area Under the Curve Spirometry Analysis in the International Journal of Chronic Obstructive Pulmonary Disease - PR Newswire

Click here to get full coverage on Theravance Biopharma Inc (TBPH) Q1 2025 Earnings Call Highlights: Strong Sales Growth and ... - Yahoo Finance

Theravance Biopharma Inc (TBPH) Q1 2025 Earnings Call Highlights: Strong Sales Growth and ...  Yahoo Finance

Theravance Biopharma Inc (TBPH) Q1 2025 Earnings Call Highlights: Strong Sales Growth and ... - Yahoo Finance

Click here to get full coverage on Theravance Biopharma, Inc. Reports Record Fourth Quarter and Full Year 2024 Financial Results - PR Newswire

Theravance Biopharma, Inc. Reports Record Fourth Quarter and Full Year 2024 Financial Results  PR Newswire

Theravance Biopharma, Inc. Reports Record Fourth Quarter and Full Year 2024 Financial Results - PR Newswire

Click here to get full coverage on Theravance Biopharma to Participate in an Upcoming Investor Conference - PR Newswire

Theravance Biopharma to Participate in an Upcoming Investor Conference  PR Newswire

Theravance Biopharma to Participate in an Upcoming Investor Conference - PR Newswire

Click here to get full coverage on BTIG Maintains Theravance Biopharma(TBPH.US) With Buy Rating, Raises Target Price to $25 - 富途牛牛

BTIG Maintains Theravance Biopharma(TBPH.US) With Buy Rating, Raises Target Price to $25  富途牛牛

BTIG Maintains Theravance Biopharma(TBPH.US) With Buy Rating, Raises Target Price to $25 - 富途牛牛

Click here to get full coverage on Theravance Biopharma Inc (TBPH) Q1 2025 Earnings Report Preview: What To Expect - Yahoo Finance

Theravance Biopharma Inc (TBPH) Q1 2025 Earnings Report Preview: What To Expect  Yahoo Finance

Theravance Biopharma Inc (TBPH) Q1 2025 Earnings Report Preview: What To Expect - Yahoo Finance

Click here to get full coverage on Theravance Biopharma, Inc. (TBPH) Stock Analysis: A Look at Its Promising 63.98% Upside Potential - DirectorsTalk Interviews

Theravance Biopharma, Inc. (TBPH) Stock Analysis: A Look at Its Promising 63.98% Upside Potential  DirectorsTalk Interviews

Theravance Biopharma, Inc. (TBPH) Stock Analysis: A Look at Its Promising 63.98% Upside Potential - DirectorsTalk Interviews

Click here to get full coverage on Theravance Biopharma Sets Q1 2025 Earnings Date: Key Financial Results Coming May 8 - Stock Titan

Theravance Biopharma Sets Q1 2025 Earnings Date: Key Financial Results Coming May 8  Stock Titan

Theravance Biopharma Sets Q1 2025 Earnings Date: Key Financial Results Coming May 8 - Stock Titan

Click here to get full coverage on Theravance and Viatris settle patent dispute with Eugia Pharma - Seeking Alpha

Theravance and Viatris settle patent dispute with Eugia Pharma  Seeking Alpha

Theravance and Viatris settle patent dispute with Eugia Pharma - Seeking Alpha

Click here to get full coverage on Theravance Biopharma: Clinical Progress Is Not Enough To Make It Attractive - Seeking Alpha

Theravance Biopharma: Clinical Progress Is Not Enough To Make It Attractive  Seeking Alpha

Theravance Biopharma: Clinical Progress Is Not Enough To Make It Attractive - Seeking Alpha

Click here to get full coverage on Theravance Biopharma, Inc. Reports Third Quarter 2024 Financial Results and Announces Initiatives to Unlock Shareholder Value - PR Newswire

Theravance Biopharma, Inc. Reports Third Quarter 2024 Financial Results and Announces Initiatives to Unlock Shareholder Value  PR Newswire

Theravance Biopharma, Inc. Reports Third Quarter 2024 Financial Results and Announces Initiatives to Unlock Shareholder Value - PR Newswire

Click here to get full coverage on Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million | TBPH Stock News - GuruFocus

Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million | TBPH Stock News  GuruFocus

Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million | TBPH Stock News - GuruFocus

Click here to get full coverage on Theravance Biopharma Sells Trelegy Royalty Interest to GSK - TipRanks

Theravance Biopharma Sells Trelegy Royalty Interest to GSK  TipRanks

Theravance Biopharma Sells Trelegy Royalty Interest to GSK - TipRanks

Click here to get full coverage on Theravance Biopharma Gains Milestone Payment from Viatris - TipRanks

Theravance Biopharma Gains Milestone Payment from Viatris  TipRanks

Theravance Biopharma Gains Milestone Payment from Viatris - TipRanks

Click here to get full coverage on BTIG maintains buy rating on Theravance Biopharma stock - Investing.com

BTIG maintains buy rating on Theravance Biopharma stock  Investing.com

BTIG maintains buy rating on Theravance Biopharma stock - Investing.com

Click here to get full coverage on Theravance Biopharma Presents Two New Ampreloxetine Analyses in Oral Session at the American Academy of Neurology 2025 Annual Meeting - PR Newswire

Theravance Biopharma Presents Two New Ampreloxetine Analyses in Oral Session at the American Academy of Neurology 2025 Annual Meeting  PR Newswire

Theravance Biopharma Presents Two New Ampreloxetine Analyses in Oral Session at the American Academy of Neurology 2025 Annual Meeting - PR Newswire

Click here to get full coverage on Here's Why We're Not At All Concerned With Theravance Biopharma's (NASDAQ:TBPH) Cash Burn Situation - Yahoo Finance

Here's Why We're Not At All Concerned With Theravance Biopharma's (NASDAQ:TBPH) Cash Burn Situation  Yahoo Finance

Here's Why We're Not At All Concerned With Theravance Biopharma's (NASDAQ:TBPH) Cash Burn Situation - Yahoo Finance

Click here to get full coverage on Theravance's Q1 Loss Wider Than Expected, Revenues Rise Y/Y - Zacks Investment Research

Theravance's Q1 Loss Wider Than Expected, Revenues Rise Y/Y  Zacks Investment Research

Theravance's Q1 Loss Wider Than Expected, Revenues Rise Y/Y - Zacks Investment Research

Click here to get full coverage on Theravance Biopharma Settles Patent Litigation with Eugia - TipRanks

Theravance Biopharma Settles Patent Litigation with Eugia  TipRanks

Theravance Biopharma Settles Patent Litigation with Eugia - TipRanks

Click here to get full coverage on Theravance Biopharma announces Viatris approval for Yupelri in China - TipRanks

Theravance Biopharma announces Viatris approval for Yupelri in China  TipRanks

Theravance Biopharma announces Viatris approval for Yupelri in China - TipRanks

Click here to get full coverage on Theravance Biopharma price target raised to $25 from $24 at BTIG - TipRanks

Theravance Biopharma price target raised to $25 from $24 at BTIG  TipRanks

Theravance Biopharma price target raised to $25 from $24 at BTIG - TipRanks

Click here to get full coverage on Theravance Biopharma, Inc. Highlights 2022 Accomplishments and 2023 Key Targets - PR Newswire

Theravance Biopharma, Inc. Highlights 2022 Accomplishments and 2023 Key Targets  PR Newswire

Theravance Biopharma, Inc. Highlights 2022 Accomplishments and 2023 Key Targets - PR Newswire

Click here to get full coverage on Theravance Biopharma to Present New Ampreloxetine Data at the 2023 International Congress of Parkinson's Disease and Movement Disorders - PR Newswire

Theravance Biopharma to Present New Ampreloxetine Data at the 2023 International Congress of Parkinson's Disease and Movement Disorders  PR Newswire

Theravance Biopharma to Present New Ampreloxetine Data at the 2023 International Congress of Parkinson's Disease and Movement Disorders - PR Newswire

Click here to get full coverage on Theravance Biopharma to Present New Ampreloxetine Data at the 34th International Symposium on The Autonomic Nervous System - PR Newswire

Theravance Biopharma to Present New Ampreloxetine Data at the 34th International Symposium on The Autonomic Nervous System  PR Newswire

Theravance Biopharma to Present New Ampreloxetine Data at the 34th International Symposium on The Autonomic Nervous System - PR Newswire

Click here to get full coverage on Theravance Biopharma Announces Results from the Phase 4 YUPELRI® PIFR-2 Study in Patients with Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD) - PR Newswire

Theravance Biopharma Announces Results from the Phase 4 YUPELRI® PIFR-2 Study in Patients with Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD)  PR Newswire

Theravance Biopharma Announces Results from the Phase 4 YUPELRI® PIFR-2 Study in Patients with Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD) - PR Newswire

Click here to get full coverage on Theravance Biopharma, Inc. Announces Orphan Drug Designation Granted to Ampreloxetine for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Patients with Multiple System Atrophy - PR Newswire

Theravance Biopharma, Inc. Announces Orphan Drug Designation Granted to Ampreloxetine for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Patients with Multiple System Atrophy  PR Newswire

Theravance Biopharma, Inc. Announces Orphan Drug Designation Granted to Ampreloxetine for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Patients with Multiple System Atrophy - PR Newswire

Click here to get full coverage on 5 Small Drug Stocks to Buy as Trump Gets Re-Elected - Yahoo Finance

5 Small Drug Stocks to Buy as Trump Gets Re-Elected  Yahoo Finance

5 Small Drug Stocks to Buy as Trump Gets Re-Elected - Yahoo Finance

Click here to get full coverage on Theravance Biopharma, Inc. Announces Appointment of Jeremy Grant to Board of Directors - PR Newswire

Theravance Biopharma, Inc. Announces Appointment of Jeremy Grant to Board of Directors  PR Newswire

Theravance Biopharma, Inc. Announces Appointment of Jeremy Grant to Board of Directors - PR Newswire

Click here to get full coverage on Long noncoding RNAs heat shock RNA omega nucleates TBPH and promotes intestinal stem cell differentiation upon heat shock - ScienceDirect.com

Long noncoding RNAs heat shock RNA omega nucleates TBPH and promotes intestinal stem cell differentiation upon heat shock  ScienceDirect.com

Long noncoding RNAs heat shock RNA omega nucleates TBPH and promotes intestinal stem cell differentiation upon heat shock - ScienceDirect.com

Click here to get full coverage on Aggravated visual toxicity in zebrafish larvae upon co-exposure to titanium dioxide nanoparticles and bis(2-ethylhexyl)-2,3,4,5-tetrabromophthalate - ScienceDirect.com

Aggravated visual toxicity in zebrafish larvae upon co-exposure to titanium dioxide nanoparticles and bis(2-ethylhexyl)-2,3,4,5-tetrabromophthalate  ScienceDirect.com

Aggravated visual toxicity in zebrafish larvae upon co-exposure to titanium dioxide nanoparticles and bis(2-ethylhexyl)-2,3,4,5-tetrabromophthalate - ScienceDirect.com

Click here to get full coverage on Theravance Biopharma, Inc. Announces Enrollment of First Patient in YUPELRI® Phase 4 Study - PR Newswire

Theravance Biopharma, Inc. Announces Enrollment of First Patient in YUPELRI® Phase 4 Study  PR Newswire

Theravance Biopharma, Inc. Announces Enrollment of First Patient in YUPELRI® Phase 4 Study - PR Newswire

Click here to get full coverage on Effects of novel brominated flame retardant TBPH and its metabolite TBMEHP on human vascular endothelial cells: Implication for human health risks - ScienceDirect.com

Effects of novel brominated flame retardant TBPH and its metabolite TBMEHP on human vascular endothelial cells: Implication for human health risks  ScienceDirect.com

Effects of novel brominated flame retardant TBPH and its metabolite TBMEHP on human vascular endothelial cells: Implication for human health risks - ScienceDirect.com

Click here to get full coverage on Wall Street Analysts Predict a 90.53% Upside in Theravance Bio (TBPH): Here's What You Should Know - Nasdaq

Wall Street Analysts Predict a 90.53% Upside in Theravance Bio (TBPH): Here's What You Should Know  Nasdaq

Wall Street Analysts Predict a 90.53% Upside in Theravance Bio (TBPH): Here's What You Should Know - Nasdaq

Click here to get full coverage on Bis (2-ethylhexyl)-2,3,4,5-tetrabromophthalate showed poor penetrability but increased the permeability of blood brain barrier: Evidences from in vitro and in vivo studies - ScienceDirect.com

Bis (2-ethylhexyl)-2,3,4,5-tetrabromophthalate showed poor penetrability but increased the permeability of blood brain barrier: Evidences from in vitro and in vivo studies  ScienceDirect.com

Bis (2-ethylhexyl)-2,3,4,5-tetrabromophthalate showed poor penetrability but increased the permeability of blood brain barrier: Evidences from in vitro and in vivo studies - ScienceDirect.com

Click here to get full coverage on Interview with the Chairman and CEO: Theravance Biopharma Inc. (NASDAQ:TBPH) - The Wall Street Transcript

Interview with the Chairman and CEO: Theravance Biopharma Inc. (NASDAQ:TBPH)  The Wall Street Transcript

Interview with the Chairman and CEO: Theravance Biopharma Inc. (NASDAQ:TBPH) - The Wall Street Transcript

Click here to get full coverage on Theravance Bio (TBPH) Down 6.1% Since Last Earnings Report: Can It Rebound? - Yahoo Finance

Theravance Bio (TBPH) Down 6.1% Since Last Earnings Report: Can It Rebound?  Yahoo Finance

Theravance Bio (TBPH) Down 6.1% Since Last Earnings Report: Can It Rebound? - Yahoo Finance

Click here to get full coverage on Characterization of the Fundulus heteroclitus embryo transcriptional response and development of a gene expression-based fingerprint of exposure for the alternative flame retardant, TBPH (bis (2-ethylhexyl)-tetrabromophthalate) - ScienceDirect.com

Characterization of the Fundulus heteroclitus embryo transcriptional response and development of a gene expression-based fingerprint of exposure for the alternative flame retardant, TBPH (bis (2-ethylhexyl)-tetrabromophthalate)  ScienceDirect.com

Characterization of the Fundulus heteroclitus embryo transcriptional response and development of a gene expression-based fingerprint of exposure for the alternative flame retardant, TBPH (bis (2-ethylhexyl)-tetrabromophthalate) - ScienceDirect.com

Click here to get full coverage on on the bioavailability and toxicity of bis(2-ethylhexyl)-2,3,4,5-tetrabromophthalate (TBPH) in developing zebrafish - ScienceDirect.com

on the bioavailability and toxicity of bis(2-ethylhexyl)-2,3,4,5-tetrabromophthalate (TBPH) in developing zebrafish  ScienceDirect.com

on the bioavailability and toxicity of bis(2-ethylhexyl)-2,3,4,5-tetrabromophthalate (TBPH) in developing zebrafish - ScienceDirect.com

Click here to get full coverage on theravance biopharma settles patent litigation with eugia pharma - Investing.com India

theravance biopharma settles patent litigation with eugia pharma  Investing.com India

theravance biopharma settles patent litigation with eugia pharma - Investing.com India

Click here to get full coverage on BTIG starts Theravance Biopharma stock on BUY, cites 'pivotal' data for ampreloxetine - Investing.com

BTIG starts Theravance Biopharma stock on BUY, cites 'pivotal' data for ampreloxetine  Investing.com

BTIG starts Theravance Biopharma stock on BUY, cites 'pivotal' data for ampreloxetine - Investing.com

Click here to get full coverage on Theravance Biopharma, Inc. Announces Top-line Results from a Phase 3 Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension - PR Newswire

Theravance Biopharma, Inc. Announces Top-line Results from a Phase 3 Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension  PR Newswire

Theravance Biopharma, Inc. Announces Top-line Results from a Phase 3 Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension - PR Newswire

Theravance Biopharma Inc (TBPH)

Price Chart

Key Statistics

Technicals

About TBPH

Latest News

Theravance Biopharma Announces Approval of YUPELRI® (revefenacin) by China's NMPA - PR Newswire

TBPH-induced lung injury is induced by mitochondrial-derived ds-DNA-mediated inflammatory response - ScienceDirect.com

TBPH to Sell Remaining Trelegy Royalty Interest to GSK, Stock Rises - Yahoo Finance

Advanced Charts

Top Gainers

Top Losers